Shanghai Haohai Biological Technology Management
Management criteria checks 4/4
Shanghai Haohai Biological Technology's CEO is Jianying Wu, appointed in Jul 2010, has a tenure of 14.33 years. directly owns 3.68% of the company’s shares, worth HK$543.90M. The average tenure of the management team and the board of directors is 9.9 years and 11 years respectively.
Key information
Jianying Wu
Chief executive officer
CN¥1.9m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 14.3yrs |
| CEO ownership | 3.7% |
| Management average tenure | 9.9yrs |
| Board average tenure | 11yrs |
Recent management updates
Recent updates
We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease
Jul 25
Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All
May 22Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Apr 17Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?
Feb 12Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Nov 14Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 28We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt
Mar 09These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Nov 25Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 30Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price
May 08Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Apr 19Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)
Mar 04Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Mar 03Is Shanghai Haohai Biological Technology (HKG:6826) A Risky Investment?
Jan 10Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Oct 08Here's Why Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt Responsibly
Jul 07Analysts Have Just Cut Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Revenue Estimates By 14%
May 27These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Apr 04Investors Who Bought Shanghai Haohai Biological Technology (HKG:6826) Shares A Year Ago Are Now Up 58%
Mar 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | CN¥430m |
| Jun 30 2024 | n/a | n/a | CN¥446m |
| Mar 31 2024 | n/a | n/a | CN¥432m |
| Dec 31 2023 | CN¥2m | n/a | CN¥416m |
| Sep 30 2023 | n/a | n/a | CN¥346m |
| Jun 30 2023 | n/a | n/a | CN¥315m |
| Mar 31 2023 | n/a | n/a | CN¥226m |
| Dec 31 2022 | CN¥2m | CN¥855k | CN¥180m |
| Sep 30 2022 | n/a | n/a | CN¥203m |
| Jun 30 2022 | n/a | n/a | CN¥192m |
| Mar 31 2022 | n/a | n/a | CN¥272m |
| Dec 31 2021 | CN¥1m | CN¥845k | CN¥352m |
| Sep 30 2021 | n/a | n/a | CN¥428m |
| Jun 30 2021 | n/a | n/a | CN¥434m |
| Mar 31 2021 | n/a | n/a | CN¥370m |
| Dec 31 2020 | CN¥1m | CN¥768k | CN¥230m |
| Sep 30 2020 | n/a | n/a | CN¥232m |
| Jun 30 2020 | n/a | n/a | CN¥216m |
| Mar 31 2020 | n/a | n/a | CN¥279m |
| Dec 31 2019 | CN¥2m | CN¥742k | CN¥371m |
| Sep 30 2019 | n/a | n/a | CN¥353m |
| Jun 30 2019 | n/a | n/a | CN¥386m |
| Mar 31 2019 | n/a | n/a | CN¥375m |
| Dec 31 2018 | CN¥1m | CN¥712k | CN¥415m |
| Sep 30 2018 | n/a | n/a | CN¥411m |
| Jun 30 2018 | n/a | n/a | CN¥408m |
| Mar 31 2018 | n/a | n/a | CN¥390m |
| Dec 31 2017 | CN¥1m | CN¥583k | CN¥372m |
Compensation vs Market: Jianying's total compensation ($USD263.42K) is below average for companies of similar size in the Hong Kong market ($USD488.63K).
Compensation vs Earnings: Jianying's compensation has been consistent with company performance over the past year.
CEO
Jianying Wu (60 yo)
14.3yrs
Tenure
CN¥1,904,800
Compensation
Dr. Jianying Wu has been General Manager of Shanghai Haohai Biological Technology Co., Ltd. since July 23, 2010 and has been its Executive Director since December 2014. Mr. Wu served as a Director at Shang...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 14.3yrs | CN¥1.89m | 3.65% HK$ 538.3m | |
| GM & Executive Director | 14.3yrs | CN¥1.90m | 3.68% HK$ 543.9m | |
| CFO & Executive Director | 7.9yrs | CN¥1.45m | 0.036% HK$ 5.4m | |
| Executive Director | 9.9yrs | CN¥1.26m | 0.26% HK$ 38.0m | |
| Joint Company Secretary | 4.9yrs | CN¥868.70k | 0.0044% HK$ 652.4k | |
| Deputy General Manager | 10.2yrs | CN¥912.50k | 0.012% HK$ 1.8m | |
| Joint Company Secretary | 10yrs | no data | no data |
9.9yrs
Average Tenure
49yo
Average Age
Experienced Management: 6826's management team is seasoned and experienced (9.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 14.3yrs | CN¥1.89m | 3.65% HK$ 538.3m | |
| GM & Executive Director | 14.3yrs | CN¥1.90m | 3.68% HK$ 543.9m | |
| CFO & Executive Director | 7.8yrs | CN¥1.45m | 0.036% HK$ 5.4m | |
| Executive Director | 14.3yrs | CN¥1.26m | 0.26% HK$ 38.0m | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Non Executive Director | 14.3yrs | no data | 47.36% HK$ 7.0b | |
| Non-Executive Director | 14.3yrs | CN¥150.00k | 1.21% HK$ 179.3m | |
| Chairman of the Supervisory Committee | 14.3yrs | no data | 1.21% HK$ 179.3m | |
| Independent Non-Executive Director | 4.4yrs | CN¥150.00k | no data | |
| Independent Non-Executive Director | 4.4yrs | CN¥150.00k | no data | |
| Independent Non-Executive Director | 4.4yrs | CN¥150.00k | no data | |
| Independent Non-Executive Director | 4.4yrs | CN¥150.00k | no data |
11.0yrs
Average Tenure
52.5yo
Average Age
Experienced Board: 6826's board of directors are seasoned and experienced ( 11 years average tenure).